A New Hope in Lung Cancer Treatment

Black Diamond Therapeutics has shared some promising news about their drug, silevertinib. It's being tested on people with a specific type of lung cancer. The results from the second phase of trials show that 60% of patients responded well to the treatment. This includes 25 partial responses and one complete response. The trial involved patients taking a daily dose of 200mg of silevertinib. The data was collected up until November 3, 2025, with an average follow-up time of 7. 2 months. The study is still ongoing, so more data is expected in the future. The drug also showed good results in controlling the cancer's spread to the brain, with an 86% response rate. Most patients experienced some side effects, but nothing new or unexpected. Common side effects included rash, mouth sores, diarrhea, and nail infections. Black Diamond plans to share more detailed results, including how long the responses last and how long the cancer doesn't get worse, at a medical meeting in the second half of 2026. They are also looking into partnerships to further develop the drug. In other news, the company is planning to start a new trial for a different type of brain cancer called glioblastoma. This trial is expected to start in the first half of 2026 and will involve around 150 patients. Financially, Black Diamond has enough money to cover its expenses until at least the second half of 2028. Despite the promising news, the company's stock price has dropped by 23. 77%, trading at $2. 62 at the time of this report.